Therapeutic Effect of Moxifloxacin versus Azithromycin on Refractory Chronic Endometritis

Therapeutic Effect of Moxifloxacin versus Azithromycin on Refractory Chronic Endometritis - Therapeutic Effect of Moxifloxacin versus Azithromycin on Refractory Chronic Endometritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031909

Enrollment

100

Registered

2018-03-26

Start date

2018-03-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Endometritis

Interventions

Oral Administration of Moxifloxacin 400mg/day for ten days Oral Administration of Azithromycin 500mg/day for three days

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Refractory Chronic Endometritis Resistant to Doxycycline and Metronidazole/Ciprofloxacin) Administration

Exclusion criteria

Exclusion criteria: Patients (i) with a history of hypersesitivity to azithromycin, moxifloxacin and/or other new quinolone agents, (ii) with a present illness of severe liver dysfunction, long QT, and/or hypokalemia, (iii) using antiarrhythmic agents, and (iv) having a pregnancy.

Design outcomes

Primary

Measure	Time frame
Histopathologic Cure Rate, Clinical Pregnancy Rate, Implantation Rate, Miscarriage Rate, Ongoing Pregnancy Rate	—

Secondary

Measure	Time frame
Live Birth Rate	—

Countries

Japan

Contacts

Public ContactKotaro Kitaya

Reproduction Clinic Osaka IVF Center

kitaya@koto.kpu-m.ac.jp0661363344

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026